Valuation : BriaCell Therapeutics Corp.

Market Cap 29.89M 25.72M 24.2M 22.11M 41.35M 2.82B 41.47M 286M 111M 1.45B 112M 110M 4.66B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 12.02M 10.35M 9.74M 8.89M 16.64M 1.14B 16.68M 115M 44.64M 582M 45.15M 44.17M 1.88B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
1 day+1.23%
1 week-5.01%
Current month-0.80%
3 months+14.39%
6 months-9.87%
Current year-49.69%
1 week 4.81
Extreme 4.81
5.25
1 month 4.67
Extreme 4.67
5.75
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
20.4
3 years 3.68
Extreme 3.68
1,447.5
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 31/10/2016
Director of Finance/CFO 54 31/01/2016
Chief Tech/Sci/R&D Officer 65 15/02/2022
Director TitleAgeSince
Director/Board Member 70 31/10/2016
Chairman 41 23/04/2019
Director/Board Member 74 06/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
07/07/26 Tax

Director

45,000 0.5173%
07/07/26 Tax

Director

15,000 0.1724%
07/07/26 Option

Chief Financial Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
+1.23%-5.01%-54.14%-99.65% 31M
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
-3.00%-2.90%+33.13%+12.54% 25.74B
+0.86%+1.65%-7.74%-14.95% 26.06B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.12%-0.27%+33.02%+149.86% 27.91B
Weighted average by Cap. -1.52%+0.18%+38.36%+137.32%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.12M -3.88M -3.54M -6.63M -452M -6.65M -45.84M -17.79M -232M -17.99M -17.6M -748M -26.31M -22.64M -21.3M -19.46M -36.4M -2.48B -36.5M -252M -97.68M -1.27B -98.8M -96.65M -4.11B
Net Debt -862K -742K -698K -638K -1.19M -81.39M -1.2M -8.25M -3.2M -41.76M -3.24M -3.17M -135M -17.87M -15.37M -14.46M -13.21M -24.72M -1.69B -24.79M -171M -66.33M -865M -67.09M -65.63M -2.79B
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
04/09/26 CA$4.930 +1.23% 3,147
03/09/26 CA$4.870 -1.62% 203
02/09/26 CA$4.950 -1.98% 6,796
01/09/26 CA$5.050 +1.61% 5,611
31/08/26 CA$4.970 -4.24% 13,588

Quarterly revenue - Rate of surprise